
Opinion|Videos|November 22, 2023
Rationale for Treatment With Momelotinib in Patients With MF
Author(s)Anthony Hunter, MD
Momelotinib, a recently approved treatment for myelofibrosis, targets multiple pathways,and offers a promising approach to improve anemia, especially in patients who did not respond optimally to previous JAK inhibitors.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma
2
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
3
ASCO 2026 Breast Cancer Highlights: Beyond the LBAs
4
Phase 3 Trial of Sacituzumab Govitecan Plus Pembrolizumab Stopped Early in First-Line mNSCLC
5




































